N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors
- PMID: 7586162
- DOI: 10.1093/carcin/16.10.2531
N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors
Abstract
The cellular transport, metabolism and biological activity of retinoids are mediated by their specific binding proteins and nuclear receptors. For an understanding of the mode of action of retinoids with potential cancer chemopreventive or other biological activity, it is important to study their interactions with these binding proteins and receptors. In our attempts to understand the action of N-(4-hydroxyphenyl)retinamide (4HPR) and other retinamides in the prevention of cancer, we observed that 4HPR binds to a serum protein with a molecular size of approximately 20,000. The retinoid, however, did not show any binding affinity for cellular retinol-binding protein (CRABP) or for cellular retinoic acid-binding protein (CRABP). However, it showed binding affinity for the nuclear receptors of retinoic acid (RARs) equivalent to 15% of that of retinoic acid. The physicochemical properties of the 4HPR binding protein in the serum were identical to those of serum retinol binding protein (RBP). Antibodies against RBP quantitatively immunoprecipitated the protein-4HPR complex, confirming that the retinoid specifically binds to RBP. Although retinol and 4HPR cross-competed for RBP binding, N-phenylretinamide, in which the 4-hydroxyl group is absent, and N-(4-methoxyphenyl)retinamide, a major cellular metabolite of 4HPR, in which the hydroxyl group is blocked, did not show affinity for the binding protein. The results indicate that the hydroxyl group of 4HPR is essential for binding of this type of retinoid to RBP. Thus, our studies suggest that serum transport of 4HPR may be facilitated by RBP. To bind more efficiently to CRBP, CRABP, or RARs/RXRs, the retinoid may require further metabolic change.
Similar articles
-
Binding of synthetic analogues of retinol and retinoic acid (CD-270 derivatives) to retinoid-binding proteins.Skin Pharmacol. 1991;4(3):132-41. doi: 10.1159/000210939. Skin Pharmacol. 1991. PMID: 1768424
-
Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6265-75. doi: 10.1158/1078-0432.CCR-04-0655. Clin Cancer Res. 2004. PMID: 15448016 Clinical Trial.
-
In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences.FEBS Lett. 1992 Aug 10;308(1):43-5. doi: 10.1016/0014-5793(92)81046-o. FEBS Lett. 1992. PMID: 1386578
-
Retinoid pathway and cancer therapeutics.Adv Drug Deliv Rev. 2010 Oct 30;62(13):1285-98. doi: 10.1016/j.addr.2010.07.003. Epub 2010 Aug 3. Adv Drug Deliv Rev. 2010. PMID: 20654663 Free PMC article. Review.
-
Cellular retinoid binding-proteins, CRBP, CRABP, FABP5: Effects on retinoid metabolism, function and related diseases.Pharmacol Ther. 2017 May;173:19-33. doi: 10.1016/j.pharmthera.2017.01.004. Epub 2017 Jan 27. Pharmacol Ther. 2017. PMID: 28132904 Free PMC article. Review.
Cited by
-
Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.J Pharm Biomed Anal. 2017 Jan 5;132:117-124. doi: 10.1016/j.jpba.2016.09.046. Epub 2016 Sep 29. J Pharm Biomed Anal. 2017. PMID: 27701038 Free PMC article.
-
Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.Anticancer Res. 2011 Mar;31(3):961-6. Anticancer Res. 2011. PMID: 21498721 Free PMC article. Clinical Trial.
-
Attempts to Improve Lipophilic Drugs' Solubility and Bioavailability: A Focus on Fenretinide.Pharmaceutics. 2024 Apr 24;16(5):579. doi: 10.3390/pharmaceutics16050579. Pharmaceutics. 2024. PMID: 38794242 Free PMC article. Review.
-
Differentiating agents in pediatric malignancies: retinoids in neuroblastoma.Curr Oncol Rep. 2000 Nov;2(6):511-8. doi: 10.1007/s11912-000-0104-y. Curr Oncol Rep. 2000. PMID: 11122886 Review.
-
The Retinoic Acid Receptor-alpha mediates human T-cell activation and Th2 cytokine and chemokine production.BMC Immunol. 2008 Apr 16;9:16. doi: 10.1186/1471-2172-9-16. BMC Immunol. 2008. PMID: 18416830 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources